Literature DB >> 10671683

Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide.

G Bacci1, A Briccoli, S Ferrari, G Saeter, D Donati, A Longhi, M Manfrini, F Bertoni, S Rimondini, C Monti, C Forni.   

Abstract

We report on the clinical course and outcome of 28 patients, treated at The Istituti Ortopedici Rizzoli between 1995 and 1997 for osteosarcoma of the extremities metastatic to the lung at presentation. The treatment for these patients was the following: primary chemotherapy with cisplatin, adriamycin and high dose of methotrexate and ifosfamide followed by simultaneous resection of primary and metastatic lesions (when feasible), and further chemotherapy. After primary chemotherapy, lung metastases disappeared in 6 patients, whereas metastases in 3 remained surgically unresectable. These 9 patients received surgical treatment of the primary tumor only. In the remaining 19 patients, after chemotherapy, a simultaneous resection of the primary and metastatic tumor was performed. The resection of metastatic lesions was complete in 18 cases and incomplete in one. Three of the 4 patients who did not achieve a tumor-free status died in a few months and one is still alive with uncontrolled disease. With a median follow-up of 32 months (19-43) of the 24 patients who achieved remission, 12 (55%) remained continuously free of disease, 11 relapsed with new metastases and 1 died of chemotherapy-related toxicity. The 2-year DFS and OS were 36% and 53% respectively. These results are much worse than those achieved in 114 contemporary patients with localised disease (2-year DFS: 81%) treated in the same period and they are superimposible to the results achieved in 23 patients previously treated with the same protocol, but with standard dose of ifosfamide (2-year DFS: 32%). However, it must be underlined that, as regards prognosis, patients with metastatic disease at presentation are a hetero-geneous group. The DFS was significantly higher for patients with only one or two metastatic lesions than for patients with 3 or more lesions (2 year DFS: 78% vs. 28%). In 12 of the 19 patients who had a complete simultaneous resection of the primary and metastatic tumor, a strong correlation between the degree of necrosis of the primary and metastatic lesions was found. We conclude that in patients with osteosarcoma of the extremity with lung metastases at presentation: a) the combination of aggressive chemotherapy with simultaneous resection of primary and metastatic tumors works very well only for those patients who present with one or two metastatic nodules whereas for patients with 3 or more pulmonary metastases the prognosis is very poor; b) within the 4-drug regimen used in this study, the increment of ifosfamide dose from 10 g/m2 to 15 g/m2 for cycle does not improve prognosis; c) the strong correlation found between the histologic response of the primary tumor and metastases supports the strategy, largely used nowadays in the neoadjuvant treatment of osteosarcoma, of tailoring postoperative chemo-therapy on the basis of the primary tumor histologic response to preoperative chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10671683     DOI: 10.3892/or.7.2.339

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  12 in total

1.  Prognosticating metastatic osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate and delayed metastasectomy: a single center experience of 102 patients.

Authors:  V Nataraj; S Rastogi; S A Khan; M C Sharma; S Agarwala; S Vishnubhatla; S Bakhshi
Journal:  Clin Transl Oncol       Date:  2016-01-07       Impact factor: 3.405

2.  Primary metastatic osteosarcoma: results of a prospective study in children given chemotherapy and interleukin-2.

Authors:  Cristina Meazza; Graziella Cefalo; Maura Massimino; Primo Daolio; Ugo Pastorino; Paolo Scanagatta; Carlo Morosi; Marta Podda; Andrea Ferrari; Monica Terenziani; Filippo Spreafico; Michela Casanova; Antonina Parafioriti; Paola Collini; Lorenza Gandola; Stefano Bastoni; Veronica Biassoni; Elisabetta Schiavello; Stefano Chiaravalli; Nadia Puma; Luca Bergamaschi; Roberto Luksch
Journal:  Med Oncol       Date:  2017-11-01       Impact factor: 3.064

3.  Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group.

Authors:  Robert E Goldsby; Timothy M Fan; Doojduen Villaluna; Lars M Wagner; Michael S Isakoff; James Meyer; R Lor Randall; Sharon Lee; Grace Kim; Mark Bernstein; Richard Gorlick; Mark Krailo; Neyssa Marina
Journal:  Eur J Cancer       Date:  2013-05-07       Impact factor: 9.162

4.  Genistein inhibits cell invasion and motility by inducing cell differentiation in murine osteosarcoma cell line LM8.

Authors:  Atsushi Nakamura; Junichi Aizawa; Kenshi Sakayama; Teruki Kidani; Tomoyo Takata; Yoshiaki Norimatsu; Hiromasa Miura; Hiroshi Masuno
Journal:  BMC Cell Biol       Date:  2012-09-26       Impact factor: 4.241

5.  Is Surgical Resection of the Primary Site Associated with an Improved Overall Survival for Patients with Primary Malignant Bone Tumors Who Have Metastatic Disease at Presentation?

Authors:  Azeem Tariq Malik; John H Alexander; Joel L Mayerson; Safdar N Khan; Thomas J Scharschmidt
Journal:  Clin Orthop Relat Res       Date:  2020-10       Impact factor: 4.755

6.  Nanoscale polysaccharide derivative as an AEG-1 siRNA carrier for effective osteosarcoma therapy.

Authors:  Fen Wang; Jia-Dong Pang; Lian-Tang Wang; Li-Ming Zhang; Lei-Lei Huang; Ran Wang; Dan Li; Kang Sun
Journal:  Int J Nanomedicine       Date:  2018-02-08

Review 7.  Efficacy of methotrexate, doxorubicin, and cisplatin for osteosarcoma: Study protocol for a systematic review of randomized controlled trial.

Authors:  Qing-Xi Tang; Lu-Chuan Wang; Yu Wang; Hong-da Gao; Zhi-Ling Hou
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

8.  Clinical Prognostic Factors and Outcome in Pediatric Osteosarcoma: Effect of Delay in Local Control and Degree of Necrosis in a Multidisciplinary Setting in Lebanon.

Authors:  Bilal Abou Ali; Mayssa Salman; Khaled M Ghanem; Fouad Boulos; Rachid Haidar; Said Saghieh; Samir Akel; Samar A Muwakkit; Hassan El-Solh; Raya Saab; Hani Tamim; Miguel R Abboud
Journal:  J Glob Oncol       Date:  2019-04

9.  Osteosarcoma of jaws.

Authors:  Mayur Chaudhary; Shweta Dixit Chaudhary
Journal:  J Oral Maxillofac Pathol       Date:  2012-05

10.  Overexpression of cytoplasmic β-catenin inhibits the metastasis of the murine osteosarcoma cell line LM8.

Authors:  Teruki Kidani; Atsushi Nakamura; Setsuya Kamei; Yoshiaki Norimatsu; Hiromasa Miura; Hiroshi Masuno
Journal:  Cancer Cell Int       Date:  2014-04-02       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.